Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial,The Lancet Oncology

当前位置： X-MOL 学术 › Lancet Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-06-28 , DOI: 10.1016/s1470-2045(24)00249-3
Salomon Tendler ₁ , Mark P Dunphy ₂ , Matthew Agee ₃ , Joseph O'Donoghue ₄ , Rania G Aly ₅ , Noura J Choudhury ₁ , Adam Kesner ₄ , Assen Kirov ₄ , Audrey Mauguen ₆ , Marina K Baine ₅ , Heiko Schoder ₂ , Wolfgang A Weber ₇ , Natasha Rekhtman ₅ , Serge K Lyashchenko ₂ , Lisa Bodei ₂ , Michael J Morris ₈ , Jason S Lewis ₉ , Charles M Rudin ₁₀ , John T Poirier ₁₁

Affiliation

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Radiology, Weill Cornell Medicine, New York, NY, USA.
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Nuclear Medicine, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medicine, New York, NY, USA; Department of Pharmacology, Weill Cornell Medicine, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.

Delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of small-cell lung cancer (SCLC) and neuroendocrine prostate cancer cells. We assessed the safety and feasibility of the DLL3-targeted imaging tracer [89Zr]Zr-DFO-SC16.56 (composed of the anti-DLL3 antibody SC16.56 conjugated to p-SCN-Bn-deferoxamine [DFO] serving as a chelator for zirconium-89) in patients with neuroendocrine-derived cancer.

中文翻译：

[89Zr]Zr-DFO-SC16.56 抗 DLL3 抗体在肺和前列腺高级别神经内分泌肿瘤患者中的成像：1/2 期首次人体试验

Delta 样配体 3 （DLL3）在小细胞肺癌（SCLC）和神经内分泌前列腺癌细胞表面异常表达。我们评估了 DLL3 靶向成像示踪剂 [89Zr]Zr-DFO-SC16.56 （由抗 DLL3 抗体 SC16.56 与 p-SCN-Bn-去铁胺 [DFO] 偶联而成，作为锆-89 的螯合剂）在神经内分泌衍生癌症患者中的安全性和可行性。

更新日期：2024-06-28

点击分享查看原文

点击收藏

阅读更多本刊新发论文